Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases-PR Newswire APAC

Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases-PR Newswire APAC

MELBOURNE, Australia, Nov. 16, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the allowance of a new composition of matter patent by the United States Patent and Trademark Office (USPTO). The new patent is the product of in-house discovery research and is central to...

Read more: Alterity announces approval of US patent for next generation compounds to treat neurodegenerative di...

More Articles …

  1. PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020-PR Newswire APAC
  2. Guardforce AI Bolsters its Services with Cybersecurity Offering and Robot as a Service Solution-PR Newswire APAC
  3. InfraRisk, Wagepay launch digital wage advance product to disrupt fintech market in Australia-PR Newswire APAC
  4. Arçelik Named Industry Leader in the Dow Jones Sustainability Index Once Again-PR Newswire APAC
  5. Gilead Sciences Announces Recipients of its First Asia HIV Research Scholar Program-PR Newswire APAC
  6. CommsChoice becomes Australia's first vendor of Contact Centre for Microsoft Teams Direct Routing-PR Newswire APAC
  7. Australian Crypto Exchange CEO Argues to Move All Long-Term Digital Asset Storage Offline-PR Newswire APAC
  8. PTC Therapeutics Announces Initiation of Phase 2/3 Clinical Trial in Australia to Evaluate PTC299 for the Treatment of COVID-19-PR Newswire APAC
  9. Lifestyle Hotel Brand TRYP by Wyndham Takes its Inaugural Trip to New Zealand-PR Newswire APAC
  10. The third CIIE concludes, $72.6 billion in intended deals for the coming year inked-PR Newswire APAC